Delving into the Latest Updates on Menthol with Synapse

Overview

Basic Info

Drug Type

Small molecule drug

Synonyms

(+-)-Menthol, (1R,2S,5R)-Menthol, Folrex

+ [8]

Target

TRPA1 x TRPM8

Mechanism

TRPA1 agonists(Transient receptor potential cation channel subfamily A member 1 agonists), TRPM8 agonists(Transient receptor potential cation channel subfamily M member 8 agonists)

Therapeutic Areas

Infectious DiseasesOtorhinolaryngologic DiseasesRespiratory Diseases+ [1]

Active Indication

BronchitisSinusitisDiagnostic agents

Inactive Indication

Adenomatous Polyposis ColiCastration-Resistant Prostatic CancerEarly gastric cancer+ [2]

Originator Organization-

Active Organization-

Inactive Organization

Nihon Pharmaceutical Co., Ltd.

Sandoz International GmbH

Shandong Bestcomm Pharmaceutical Co., Ltd.

Drug Highest PhaseApproved

First Approval Date-

Regulation-

Login to view timeline

Structure

Molecular FormulaC10H20O

InChIKeyNOOLISFMXDJSKH-WYVCTLLJSA-N

CAS Registry89-78-1

Neurovascular signaling in the skin associated with stimulation of the transient receptor potential (TRP) channels. These channels are stimulated by both temperature and naturally occurring bioactive agents found in mint, chili peppers, garlic, etc. The aim of the study is to examine how topically applied TRP channel agonists including menthol, capsaicin and camphor impact neurovascular responses in the skin.

Start Date15 Jun 2024

Sponsor / Collaborator

The Pennsylvania State University

100 Clinical Results associated with Menthol

Login to view more data

100 Translational Medicine associated with Menthol

Login to view more data

100 Patents (Medical) associated with Menthol

Login to view more data

2,760

Literatures (Medical) associated with Menthol

01 Feb 2025·Intensive and Critical Care Nursing

Thirst in adult patients in the intensive care unit: A scoping review

Review

Author: Spronk, Peter E ; Spronk, Peter E. ; Flim, Marleen ; Rustøen, Tone ; Blackwood, Bronagh

PURPOSE:

To review the literature on thirst in intensive care unit (ICU) patients and report potential causes, risk factors, diagnosis and measurement tools, as well as potential co-occurrence with other distressing symptoms, and the management of thirst in the ICU.

DESIGN:

A scoping review employing the Joanna Briggs Institute methodology.

METHODS:

PubMed, MEDLINE, EMBASE and CINAHL were searched from inception to April 2024. Any type of empirical study reporting thirst or associated xerostomia in adult patients (≥18 years) admitted to an ICU or high dependency unit for more than 24 h were included.

RESULTS:

The search yielded 907 unique records, and after evaluating 65 full-text publications, 21 studies were included. Thirst intensity was addressed most often (eleven studies), whereas the experience (or quality) of thirst and the validation of a measurement instrument, were addressed in only one study. Although co-occurrence of symptoms was addressed in four studies, only one pilot study looked into the interaction of thirst with other symptoms. Intervention studies have been focussing primarily on mouth-care interventions.

CONCLUSION:

Thirst is a distressing symptom in the ICU, with reported high prevalence and intensity. Knowledge about its causes, interventions that incorporate minimising its risk, occurrence and intensity are limited.

IMPLICATIONS FOR CLINICAL PRACTICE:

Health care providers should acknowledge thirst as a prominent symptom for ICU patients. They should possess knowledge on the factors that potentially evoke or aggravate thirst. Regular and timely relief of thirst by oral care with cold swabs and the application of menthol can be regarded as a first choice of intervention.

01 Feb 2025·NEUROPHARMACOLOGY

Neural modulation by nicotine aerosols and the role of flavor additives: insights from local field potentials in mice

Article

Author: Zhu, Yunhe ; Shi, Qingzhao ; Mao, Jian ; Wang, Junmin ; Chai, Guobi ; Li, Ying ; Hu, Nengwei ; Sun, Jingping ; Fan, Wu ; Xie, Jianping ; Zhang, Qidong

Research on nicotine's neurobiological effects has rarely focused on aerosols, despite their primary role in tobacco product consumption. Here, we utilized in vivo electrophysiology to examine brain activity in mice exposed to nicotine aerosols, both alone and with flavor additives (citric acid and menthol). Local field potential (LFP) recordings from the nucleus accumbens (NAc), basolateral amygdala (BLA), ventral tegmental area (VTA), and ventral posteromedial nucleus (VPM) were analyzed under saline, nicotine, nicotine with citric acid(CA + NIC), and nicotine with menthol(MENT + NIC) conditions. Nicotine exposure significantly reduced power spectral density (PSD) in the NAc-Alpha, NAc-Beta, and BLA-Beta bands, unaffected by flavor additives. Coherence between key brain regions (e.g., VPM-VTA in Beta, VPM-BLA in Alpha) also decreased with nicotine but was restored with citric acid or menthol, suggesting their role in mitigating nicotine's disruptive effects on neural synchronization. Our findings show that LFPs can effectively capture nicotine's neural effects and highlight the modulatory role of flavor additives, offering new insights into nicotine exposure management and tobacco product design.

01 Jan 2025·DRUG AND ALCOHOL DEPENDENCE

Prevalence and correlates of negative side effects from vaping nicotine: Findings from the 2020 ITC four country smoking and vaping survey

Article

Author: Hyland, Andrew ; Taylor, Eve ; Cummings, K Michael ; Bansal-Travers, Maansi ; Gravely, Shannon ; Hughes, Laura ; Yong, Hua-Hie ; Borland, Ron ; Brose, Leonie S

INTRODUCTION:

This study examined prevalence and correlates of self-reported negative side effects from nicotine vaping product (NVP) use among people who currently or recently vape.

METHODS:

This cross-sectional study analysed data from 3906 adults (aged 18+ years) from the 2020 ITC Four Country Smoking and Vaping Survey (Canada, US, England and Australia) who reported they had ever smoked cigarettes and were either currently vaping daily/weekly or had vaped in the last month. Participants were asked about experiencing and seeking medical advice for any negative side effects from vaping in the past month. Logistic regressions were used to estimate prevalence and identify correlates.

RESULTS:

Overall, 87.1 % reported no negative side effects from vaping. The most common side effects were throat irritation (5.8 %), cough (5.5 %), and mouth irritation (4.1 %). The top two that led to seeking medical advice were: mouth irritation (46.8 %) and loss of taste (45.2 %). Those more likely to self-report side effects were younger, male, currently smoking (vs quit), vaping for <6 months (vs >1 year), using disposables or cartridges/pods (vs tanks), using vapes with nicotine (vs without nicotine), using menthol/mint flavour (vs sweet flavour), currently smoking (vs quit), believing vaping causes various diseases (e.g., heart disease), and believing that vaping is equally/more harmful than smoking.

CONCLUSION:

Negative side effects associated with NVP use were rare and mainly minor in all four countries. Shorter duration of vaping, concurrent smoking while vaping and perceptions of greater vaping harms relative to smoking were associated with more reported negative side effects attributed to vaping.

73

News (Medical) associated with Menthol

05 Nov 2024

·www.drugs.com

Banning Menthol Cigarettes Might Drive Smokers to Quit-Smoking Therapies

TUESDAY, Nov. 5, 2024 -- Banning menthol cigarettes could help convince smokers quit the habit, a new study finds. People who prefer menthol cigarettes would rather buy nicotine gum or other nicotine replacement therapies than switch to traditional tobacco cigarettes, researchers reported recently in the journal Drug and Alcohol Dependence . In addition, menthol cigarette smokers were less likely to use e-cigarettes as a substitute if menthol vaping products are also restricted, researchers found. “I think the most important conclusion from this study is that we can improve health outcomes by emphasizing policies that reduce sales of flavored products and increase accessibility of nicotine replacement therapies,” said researcher Roberta Freitas-Lemos , an assistant professor at the Virginia Tech Fralin Biomedical Research Institute. More than 9 million adults -- about 32% of all smokers -- use menthol cigarettes, researchers said in background notes. Menthol makes smoking easier by reducing the harshness of cigarette smoke and cooling the throat. The Biden Administration has come under fire for delaying a proposed U.S. Food and Drug Administration ban on menthol cigarettes. In a September hearing before Congress, FDA leaders said a menthol ban is still in the works. "It's a priority for us. We followed through rule-making processes and it's presently with the White House and it continues to be a priority for us," Brian King, director of the FDA's Center for Tobacco Products, told a House Energy and Commerce Committee hearing. For the new study, researchers analyzed data from 172 people who smoke cigarettes, including 76 who only smoke menthol cigarettes and 96 who smoke non-menthol cigarettes. They also looked at 91 who use multiple types of tobacco products. The smokers were asked to use an online account to buy tobacco and nicotine products, which included replacement therapies. When menthol cigarettes weren’t available, smokers who prefer menthol were less willing to buy other types of cigarettes. Instead, they turned to nicotine replacement products like patches or gum. The study also found higher demand for high-ventilation cigarettes, which feature filter holes for airflow that make the smoke less harsh. “Cigarettes with ventilation are milder and people think they are less harmful, but it is a false perception,” Freitas-Lemos said in a Virginia Tech news release. Bans of these products could help smokers choose to quit, the researchers concluded. “It could be that people who smoke ventilated cigarettes are more responsive to one ban than another,” Freitas-Lemos said. Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.

24 Sep 2024

·www.prnewswire.com

Stop Itchy Skin in its Tracks

5 tips for relief from a board-certified dermatologist ROSEMONT, Ill., Sept. 24, 2024 /PRNewswire/ -- Itchy skin can be irritating, especially an itch that doesn't go away. There are many potential causes for itchy skin like common skin conditions such as eczema, shingles, hives, psoriasis, or bug bites, or it could be a sign of a contagious disease, like scabies or ringworm. While these causes could mean a visit to a board-certified dermatologist, there are options for self-care at home to provide itch relief. "Our first instinct is to scratch that pesky itch, but in reality, that could be making things worse by irritating your skin further," said Susan Massick, MD, FAAD, clinical associate professor of dermatology at The Ohio State University. "Everyone experiences itchy skin from time to time, but relief can be possible by following a few easy steps at home." To help soothe itchy skin, Dr. Massick and the American Academy of Dermatology recommend following these tips: Apply a cool, damp washcloth to itchy skin for about 5-10 minutes, or until the itch goes away. Take a warm colloidal oatmeal bath. This can soothe your skin, especially if the cause of your itch is chickenpox, hives, poison ivy, or sunburn. Apply a "fragrance-free" moisturizer when your skin is still damp after bathing or whenever it itches. Soaps, detergents, and other products should also be "fragrance-free" as fragrance can irritate the skin. If your moisturizer doesn't relieve the itch, apply a cooling agent, like menthol or calamine. You can also try an over-the-counter cream or gel that contains pramoxine, a topical pain reliever. Sometimes keeping these in the refrigerator also helps. Wear loose-fitting, cotton clothes. These help you stay cool and won't irritate your skin, like wool and other rough-feeling fabrics can. Avoid extreme temperature changes, as these can make itch worse. Keep your house cool during the summer and use a humidifier and avoid high heat in the winter. "If you do not find relief after trying these at-home tips, or if you notice changes to your skin, such as redness, swelling, rash, bumps, or sores, a board-certified dermatologist can diagnose the underlying condition," said Dr. Massick. "Often, itching can have more than one cause, and together we can work toward a treatment plan that offers the best results, healthier skin, and, ultimately, symptom relief." These tips are demonstrated in "How to relieve itchy skin," a video posted to the AAD website and YouTube channel. This video is part of the AAD's "Your Dermatologist Knows" series, which offers tips people can use to properly care for their skin, hair, and nails. To manage itchy skin and learn more tips, partner with a board-certified dermatologist. To find a board-certified dermatologist in your area, visit aad.org/findaderm. More Information Itchy Skin Resource Center 10 Reasons Your Skin Itches and How to Get Relief AAD B-Roll Library About the AAD Headquartered in Rosemont, Ill., the American Academy of Dermatology, founded in 1938, is the largest, most influential and most representative of all dermatologic associations. With a membership of more than 21,000 physicians worldwide, the AAD is committed to advancing the diagnosis and medical, surgical, and cosmetic treatment of the skin, hair, and nails; advocating high standards in clinical practice, education and research in dermatology; and supporting and enhancing patient care because skin, hair, and nail conditions can have a serious impact on your health and well-being. For more information, contact the AAD at (888) 462-DERM (3376) or aad.org. Follow @AADskin on Facebook, TikTok, Pinterest and YouTube and @AADskin1 on Instagram. SOURCE American Academy of Dermatology WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? 440k+ Newsrooms & Influencers 9k+ Digital Media Outlets 270k+ Journalists Opted In GET STARTED

17 Sep 2024

·www.prnewswire.com

IVIEW Therapeutics Inc. Completes Patient Recruitment for Phase 1/2 Trial of IVW-1001 Ophthalmic Eyelid Wipe in Dry Eye Disease Patients

CRANBURY, N.J., Sept. 17, 2024 /PRNewswire/ -- IVIEW Therapeutics Inc., a clinical-stage biotechnology company dedicated to advancing innovative treatments for ocular diseases, today announced the completion of patient recruitment for its Phase 1/2 clinical trial evaluating IVW-1001, a novel TRPM8 agonist delivered via ophthalmic eyelid wipe, for the treatment of signs and symptoms of dry eye disease. The company anticipates reporting topline data in the first quarter of 2025. Advancing Toward Promising Results "We are thrilled to have reached this significant milestone in our clinical development program for IVW-1001," said Houman Hemmati, MD, PhD, Chief Medical Advisor at IVIEW Therapeutics Inc. "Completing patient enrollment brings us one step closer to potentially offering a new therapeutic option for individuals suffering from dry eye disease. We are eagerly awaiting the trial results and remain optimistic about the potential impact on patient care." A Step Forward in Innovative Ophthalmic Treatments Bo Liang, PhD, MBA, Co-founder, Chairman, and CEO of IVIEW Therapeutics Inc., commented, "The completion of patient recruitment ahead of schedule is a testament to the dedication of our clinical team and the interest from the ophthalmic community. IVW-1001's novel mechanism of TRPM8 activation and its innovative delivery through an ophthalmic eyelid wipe could offer a differentiated treatment for dry eye disease worldwide. We look forward to sharing our findings as soon as they are available." About IVIEW Therapeutics Inc. IVIEW Therapeutics Inc. is a clinical-stage biotechnology company focusing on innovative ophthalmic therapeutics. Driven by the pursuit of cutting-edge science, we aim to develop differentiated products that fulfill unmet medical needs. We invest in novel mechanisms of action and advanced drug delivery technology platforms to bring forward assets with potentially superior target product profiles. Our innovative portfolio of small molecules and gene therapy assets covers dry eye, myopia, conjunctivitis, glaucoma, and presbyopia. Located in Cranbury, New Jersey, IVIEW operates a state-of-the-art 11,045 sq. ft. laboratory and office space in the Princeton area. For additional information, please visit our website at . SOURCE IVIEW Therapeutics Inc. WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? 440k+ Newsrooms & Influencers 9k+ Digital Media Outlets 270k+ Journalists Opted In GET STARTED

Clinical Study

100 Deals associated with Menthol

Login to view more data

External Link

KEGG	Wiki	ATC	Drug Bank
D04918	Menthol	R05X	DB14123

R&D Status

Approved

10 top approved records.

Login

to view more data

Indication	Country/Location	Organization	Date
Bronchitis	-	-	-
Sinusitis	-	-	-

Developing

10 top R&D records.

Login

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Pharyngitis	Phase 3	RU	Sandoz International GmbH	22 Feb 2017
Adenomatous Polyposis Coli	Phase 3	JP	Nihon Pharmaceutical Co., Ltd.	01 Sep 2011
Castration-Resistant Prostatic Cancer	Phase 3	JP	Nihon Pharmaceutical Co., Ltd.	01 Sep 2011
Early gastric cancer	Phase 3	JP	Nihon Pharmaceutical Co., Ltd.	01 Sep 2011
Gastric adenoma	Phase 3	JP	Nihon Pharmaceutical Co., Ltd.	01 Sep 2011
Diagnostic agents	Phase 1	CN	-	26 Dec 2018
Diagnostic agents	Phase 1	CN	Shandong Bestcomm Pharmaceutical Co., Ltd.	26 Dec 2018

Login to view more data

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT01855607 (CTgov)	Phase 2	Colonic Cancer \| Breast Cancer \| Peripheral Nervous System Diseases ... View more	12	placebo+menthol	ifgskeubms(uhbrggydoi) = vuvjfbqgvq nhtnobptep (cyrrupcbki, pvmiwtenom - ehyqewwexz) View more	-	11 Jul 2024
ATS2023	Not Applicable	Respiratory Insufficiency	-	Electronic Cigarette Menthol Flavoring (Menthol-flavored ECs)	ldkzmmntba(hbykxtlsoh) = reduced rvtqpwmudv (blhxwgftcr ) View more	-	21 May 2023
				Electronic Cigarette Menthol Flavoring (Non-menthol-flavored ECs)
NCT03095508 (CTgov)	Phase 3	Pharyngitis	229	Angal S, topical spray [Menthol] (Angal S (Arm A))	bxciufztmx(kdehohqqze) = bhocqybcaf mrzrrzfzcj (adaxyrxqtw, kmsuqdtijx - vyzblnqjqt) View more	-	21 Mar 2019
				ANTI-ANGIN® FORMULA, topical metered spray (ANTI-ANGIN® FORMULA (Arm B))	bxciufztmx(kdehohqqze) = ybgghqlrba mrzrrzfzcj (adaxyrxqtw, qkkjmgunfv - rccjxthwer) View more
NCT02102100 (CTgov)	Not Applicable	Nicotine Dependence	57	nicotine+menthol (Menthol-Preferring Smokers)	sanaozckyq(ldbxiujtbp) = qqsjbhcsga vvmfesvbau (hydwvzxhie, mtjhcacclu - denyzpwzgd) View more	-	20 Feb 2019
				nicotine+menthol (Non-Menthol Preferring Smokers)	sanaozckyq(ldbxiujtbp) = mbhkmikkcm vvmfesvbau (hydwvzxhie, tcxutzclak - mdhgxgnori) View more
UEGW2014	Not Applicable	Dyspepsia	-	Menthol (Patients with dyspepsia symptoms)	wsqjtszwfi(mwtptlibjg) = tinzirnqwt cbgertvpma (unsgdrlrul )	-	01 Oct 2014
				Menthol (Healthy subjects without abdominal symptoms)	wsqjtszwfi(mwtptlibjg) = tbcyifuyxd cbgertvpma (unsgdrlrul )
SFN2013	Not Applicable	-	-	Menthol	rklolaeagw(dnwxvjrxva) = egyqptfksk sloehubqlt (iynplrjoej )	-	13 Nov 2013
SFN2013	Not Applicable	-	-	Menthol	aslkhbkxse(eromwiuzvk) = tueolplasy yjvvgipvwj (jseerynrdf )	-	12 Nov 2013
SFN2013	Not Applicable	Trigeminal Nerve Injuries	-	menthol (ION-CCI rats)	bkxklenhfv(khnzvvrblz) = lhkiscfnmd ilsafdjznq (dcmrkdnjzj )	-	12 Nov 2013
				menthol (Sham group)	bkxklenhfv(khnzvvrblz) = lvvjldzmtq ilsafdjznq (dcmrkdnjzj )
SFN2011	Not Applicable	-	-	Capsaicin	rzjtarcmlq(tvitembguq) = bgbarxfnov ohddlbhrao (wabkptnmjm )	-	13 Nov 2011
				Mustard oil	rzjtarcmlq(tvitembguq) = ptqthlprfx ohddlbhrao (wabkptnmjm )
SFN2005	Not Applicable	-	-	Menthol	mzaclrjcxe(olmicrcjww) = pinhqjiyhh thbtilmjsl (fvwhnxixsf )	-	16 Nov 2005